GH Research Announces Pricing of $150 Million Public Offering
February 04, 2025 20:52 ET
|
GH Research PLC
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
GH Research Announces Proposed Public Offering
February 03, 2025 16:03 ET
|
GH Research PLC
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a...
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
February 03, 2025 07:00 ET
|
GH Research PLC
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients...
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
January 31, 2025 16:01 ET
|
GH Research PLC
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
January 10, 2025 07:00 ET
|
GH Research PLC
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint...
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery...
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 03, 2024 07:05 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
September 03, 2024 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...